|
LFA News Room
March 10, 2011
“This is a historic day for the millions
of people with lupus and their families
around the world who have waited more
than 52 years for a treatment
breakthrough for lupus. We at the LFA
applaud the FDA’s decision to approve
BENLYSTA®. BENLYSTA is the first drug
ever to be specifically developed to
treat lupus, and is a significant first
step toward reaching our goal of
developing an arsenal of new, safe,
effective, and tolerable treatments.
Today marks the beginning of a new era
of improved diagnosis, prevention, and
treatment for the disease.
Lupus Foundation of America Applauds
FDA's Decision to Approve Benlysta®
March 4, 2011
Lupus Advocates Paint Capitol Hill Purple
February 28, 2011
Advocates Seek Increased Federal Funding to Bridge the Gaps in Lupus Research, Awareness, and Education
February 25, 2011
Lupus Foundation of America Seeks Research Applications to Address the Gaps in Medical Research on Lupus
January 10, 2011
Lupus Foundation of America Achieves International Consensus on Definition of a Lupus Flare
October 27, 2010
Lupus Foundation of America Advances Clinical Research with Launch of New Online Registry
October 20, 2010
The Lupus Foundation of America Congratulates Dr. John Harley on $1.1 Million Award from the Department of Defense for Lupus Research
October 13, 2010
LFA Awards New Grants to Fund Critical Areas of Lupus Research
October 1, 2010
Lupus Foundation of America Elects Cindy Coney as Chair of the National Board of Directors
September 17, 2010
FDA Extends BENLYSTA® Decision Date to March 10, 2011
September 14, 2010
Celebrities Spotlight the Impact of Lupus on Family and Friends During the Lupus Foundation of America’s Butterfly Gala in New York City
Lupus News Room
December 3, 2010
Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for Benlysta® (Belimumab) as a Potential Treatment for Systemic Lupus Erythematosus
August 19, 2010
Human Genome Sciences and GlaxoSmithKline Announce FDA Priority Review Designation for Benlysta® (Belimumab) as a Potential Treatment for Systemic Lupus Erythematosus
|
